Anticoagulant therapy among patients with cirrhosis: a challenging attempt to maintain a delicate balance

Main Article Content

Bundarika Suwanawiboon

Abstract

-

Keywords

Article Details

Section
บทบรรณาธิการ (Editorial)

References

1. Zakeri N, Tsochatzis EA. Bleeding risk with invasive procedures in patients with cirrhosis and coagulopathy. Curr Gastroenterol Rep. 2017;19:45.
2. Allison MG, Shanholtz CB, Sachdeva A. Hematological issues in liver disease. Crit Care Clin. 2016;32:385-96.
3. Kujovich JL. Coagulopathy in liver disease: a balancing act.Hematology Am Soc Hematol Educ Program. 2015;2015:243-9.
4. Tripodi A. Hemostasis abnormalities in cirrhosis. Curr Opin Hematol. 2015;22:406-12.
5. Baccouche H, Labidi A, Fekih M, Mahjoub S, Kaabi H, Hmida S, et al. Haemostatic balance in cirrhosis. Blood Coagul Fibrinolysis. 2017;28:139-44.
6. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53-61.
7. Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res. 2012;42:459-72.
8. Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood. 2014;123:3697-705.
9. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, et al. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. Br J Haematol. 2013;162:819-26.
10. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012;10:2116-22.
11. Under the auspices of the Italian Association for the Study of Liver Diseases, the Italian Society of Internal Medicine. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis. 2016;48:455-67.
12. Vincent JL, Yagushi A, Pradier O. Platelet function in sepsis. Crit Care Med. 2002;30:S313-7.
13. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22:83-96.
14. Ferro D, Basili S, Lattuada A, Mantovani B, Bellomo A, Mannucci PM, et al. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant
activation. Ital J Gastroenterol Hepatol. 1997;29:434-40.
15. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica. 2000;85:967-72.
16. Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int. 2003;23:440-8.
17. Choi J, Kim J, Shim JH, Kim M, Nam GB. Risks versus benefits of anticoagulation for atrial fibrillation in cirrhotic patients. J Cardiovasc Pharmacol. 2017;70:255-62.
18. Lee SJ, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol. 2015;180:185-91.